A Pilot Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide (RICE) Plus Bortezomib (Velcade) in a Dose-Escalating Fashion for Patients With Relapsed or Primary Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma Who Are Candidates for Autologous Stem Cell Transplant
This study has been terminated.
( Investigator left institution. 7 patients accrued and there is insufficient data to analyze. )
Study NCT00515138
Information provided by University of California, San Francisco
First Received on August 9, 2007.
Last Updated on April 11, 2012
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
